"Efficacy and Safety of Talazoparib (TALA) or Physician's Choice of Therapy (PCT) in United States Patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) Locally Advanced/metastatic Breast Cancer (LA/MBC) in the EMBRACA Study" by Reshma Mahtani

Article

Efficacy and Safety of Talazoparib (TALA) or Physician's Choice of Therapy (PCT) in United States Patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) Locally Advanced/metastatic Breast Cancer (LA/MBC) in the EMBRACA Study

Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting (2019)

Reshma Mahtani, Baptist Health South Florida

Link

Abstract

Sami Diab, Hope S. Rugo, Lida A. Mina, Shannon Puhalla, Norah Lynn Henry, Neelima Denduluri, Denise A. Yardley, Yao Wang, Lillian Shahied Arruda, Iulia Cristina Tudor, Eric Roland Gauthier, Akos Gabor Czibere, Jennifer Keating Litton, Sara A. Hurvitz

Disciplines

Medicine and Health Sciences

Publication Date

2019

Citation Information

Reshma Mahtani. "Efficacy and Safety of Talazoparib (TALA) or Physician's Choice of Therapy (PCT) in United States Patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) Locally Advanced/metastatic Breast Cancer (LA/MBC) in the EMBRACA Study" Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting Vol. 37 Iss. 15_suppl. (2019)
Available at: http://works.bepress.com/reshma-mahtani/30/